Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Sargent

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Sound footing or slippery slope? The value of secondary analyses of randomized trialsDaniel Sargent, Axel Grothey
Annals of Surgical Oncology|January 23, 2010
Adjuvant therapy for colon cancer: learning from the past to inform the futureDaniel Sargent, Axel Grothey
Lancet (London, England)|July 17, 2007
Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?Hans-Joachim Schmoll, Daniel Sargent
Statistics in Medicine|April 20, 2016
Testing of evaluation bias for progression free survival endpoint in oncology clinical trialsYan Sun, Wenting Wu, Daniel Sargent
JAMA|September 22, 2011
Time to initiation of adjuvant chemotherapy and survival in colorectal cancerDaniel Sargent, Axel Grothey, Richard Gray
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2004
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatmentAxel Grothey, Daniel Sargent, Richard M Goldberg, et al.
The Oncologist|May 22, 2010
Blinded independent central review of the progression-free survival endpointOhad Amit, Will Bushnell, Lori Dodd, et al.
JAMA|January 16, 2002
Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trialJane C Weeks, Heidi Nelson, Shari Gelber, et al.
Clinical Trials (London, England)|May 10, 2012
Taking the long view: how to design a series of Phase III trials to maximize cumulative therapeutic benefitMarie-Cécile Le Deley, Karla V Ballman, Julien Marandet, et al.
Cancer|March 6, 2008
Systematic review of statistical methods used in molecular marker studies in cancerAndrew J Vickers, Kwang Jang, Daniel Sargent, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Sound footing or slippery slope? The value of secondary analyses of randomized trialsDaniel Sargent, Axel Grothey
Annals of Surgical Oncology|January 23, 2010
Adjuvant therapy for colon cancer: learning from the past to inform the futureDaniel Sargent, Axel Grothey
Lancet (London, England)|July 17, 2007
Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?Hans-Joachim Schmoll, Daniel Sargent
Statistics in Medicine|April 20, 2016
Testing of evaluation bias for progression free survival endpoint in oncology clinical trialsYan Sun, Wenting Wu, Daniel Sargent
JAMA|September 22, 2011
Time to initiation of adjuvant chemotherapy and survival in colorectal cancerDaniel Sargent, Axel Grothey, Richard Gray
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2004
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatmentAxel Grothey, Daniel Sargent, Richard M Goldberg, et al.
The Oncologist|May 22, 2010
Blinded independent central review of the progression-free survival endpointOhad Amit, Will Bushnell, Lori Dodd, et al.
JAMA|January 16, 2002
Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trialJane C Weeks, Heidi Nelson, Shari Gelber, et al.
Clinical Trials (London, England)|May 10, 2012
Taking the long view: how to design a series of Phase III trials to maximize cumulative therapeutic benefitMarie-Cécile Le Deley, Karla V Ballman, Julien Marandet, et al.
Cancer|March 6, 2008
Systematic review of statistical methods used in molecular marker studies in cancerAndrew J Vickers, Kwang Jang, Daniel Sargent, et al.
Pageof 5